Engflag

Iminem

Quick links to important sections

Iminem

Iminem_EN

Method of action: Bactericidal

Treatment option: Endocarditis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Iminem

The medicinal entity Iminem is the trade name for a prescription-only combination product classified as a potent anti-infective agent.

Property Description
Active ingredient Imipenem and Cilastatin
Form Sterile powder for reconstitution (for intravenous infusion)
Pharmacological class Carbapenem antibiotic
Common use Anti-infective agent (treating severe bacterial infections)
Origin Synthetic/Semi-synthetic

What Type of Medicine is Iminem?

Iminem is defined by its core component, Imipenem, which belongs to the Carbapenem antibiotic class, a powerful subgroup of beta-lactam antibiotics. The formulation also includes Cilastatin, a non-antibiotic enzyme inhibitor essential for the drug's activity. Imipenem possesses a broad spectrum of activity against a diverse range of bacterial strains. This indicates that the medicine is typically reserved for use in hospital settings to manage severe, complicated infections where a reliable, wide-ranging bacterial intervention is necessary. Iminem, manufactured by a specific pharmaceutical company, is one of the globally utilized trade names for the Imipenem/Cilastatin formulation.

Composition and Purpose of the Dual-Agent Form

The product's combination is composed of the active ingredient Imipenem and the enzyme inhibitor Cilastatin, usually supplied as a sterile powder for reconstitution for intravenous infusion. This dual structure is mandatory because the potent Imipenem is susceptible to rapid deactivation by a natural kidney enzyme. Cilastatin acts strictly as a renal dehydropeptidase inhibitor to protect the Imipenem component. This inhibition ensures adequate therapeutic drug levels reach the infection site. This protective function is crucial to the medicine's general purpose: ensuring a reliable and potent broad-spectrum anti-infective response against challenging pathogens. The product's stability and efficacy profile make it a critical agent for treating complicated infections, such as severe respiratory or intra-abdominal infections.

Regulatory References

  1. NIH/DailyMed Imipenem/Cilastatin

What side effects are possible with Iminem?

Iminem (imipenem and cilastatin) is a potent antibiotic used to treat severe bacterial infections. Like all medications, it can cause side effects, ranging from common, minor issues to rare, serious adverse events.

Common Side Effects

Most reported side effects are generally mild and temporary. These frequently include injection site reactions such as pain, redness, or induration (hardening) at the site of intravenous infusion. Gastrointestinal issues like nausea, vomiting, and diarrhea are also commonly reported.

Serious Side Effects and Warnings

Central Nervous System Effects

Iminem can increase the risk of seizures and other central nervous system (CNS) adverse reactions, including confusion and myoclonic activity (muscle twitching). This risk is higher in patients with a history of seizures, pre-existing CNS disorders (such as brain lesions or a history of stroke), or kidney impairment (renal insufficiency). Patients with a history of seizures should continue their anticonvulsant therapy as prescribed.

Hypersensitivity and Allergic Reactions

Serious and potentially fatal allergic (anaphylactic) reactions have been reported. Symptoms may include rash, hives, difficulty breathing or swallowing, and swelling of the face, lips, tongue, or throat. Iminem is contraindicated in patients with a known hypersensitivity to the drug components or to other antibiotics in the carbapenem class, or who have experienced a severe allergic reaction to other beta-lactam antibiotics (e.g., penicillins or cephalosporins).

Gastrointestinal Concerns

Antibiotic use, including Iminem, can lead to the overgrowth of a bacterium called Clostridium difficile, causing C. difficile-associated diarrhea (CDAD). This can range in severity from mild diarrhea to life-threatening colitis and may occur during or several months after treatment. Patients experiencing severe, watery, or bloody diarrhea should seek immediate medical attention.

Precautions

Before receiving Iminem, patients should inform their healthcare provider of any history of allergies, kidney disease, or CNS disorders. Co-administration of Iminem with valproic acid or divalproex sodium is generally not recommended as it can significantly reduce the concentration of valproic acid, increasing the risk of breakthrough seizures. If you experience new or worsening side effects, contact your healthcare professional immediately.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Iminem (Imipenem and Cilastatin) defines overdose based on documented clinical signs, mandated emergency actions, and specific risk factors. Overexposure, particularly when recommended dosages are exceeded, is primarily associated with Central Nervous System (CNS) toxicity.

Overdose manifestations may include nausea, vomiting, diarrhea, confusional states, and myoclonic activity (focal tremors). The most severe outcome explicitly linked to overdosage in regulatory documents is the occurrence of seizures (convulsions).

When to seek immediate medical help

Immediate medical attention is required in all cases of suspected overdosage. Regulators mandate that the drug must be discontinued promptly. Medical support should focus on symptomatic and supportive treatment and a neurological evaluation to manage any developing CNS signs. If seizures or myoclonic activity occur, anticonvulsant therapy may be required.

Population-Specific Overdose Considerations

The risk of severe CNS adverse reactions is significantly increased in patients with compromised renal function (due to potential drug accumulation) and in those with pre-existing CNS disorders. Regulatory labeling explicitly states that no specific antidote is known for an overdosage of Imipenem and Cilastatin.

Therapeutic Uses of Iminem

What Iminem Treats: Main Uses and Benefits

Iminem is used to help manage a range of serious infections in situations where patients experience symptomatic discomfort. The medication is generally reserved for conditions associated with acute or disruptive episodes where infections are complicated, widespread, or cause symptoms that interfere with daily functioning.

Primary Therapeutic Domains

This medication is commonly used across domains involving significant symptomatic burden, including severe lower respiratory tract infections, complex intra-abdominal infections, infections of the bone and joint, and systemic conditions like sepsis. Its use provides supportive benefit in achieving control over the infection to help ease acute symptoms like high fever and systemic manifestations. This is commonly used in clinical settings that involve acute or unstable symptom patterns where symptoms that interfere with daily functioning are associated with challenging pathogens.

“The primary benefit provided is supporting the body during episodes of heightened discomfort and contributing to easing the overall symptom load associated with serious bacterial illness.”

Supportive Management

Iminem contributes to easing the overall symptom load by focusing on symptoms related to systemic imbalance, which often cluster into symptoms that interfere with daily functioning. This may assist with managing symptoms related to resilient pathogens, supporting general well-being during symptomatic phases.

Quick Fact: Relief for Severe Symptoms
Symptom Focus Symptoms related to systemic imbalance (high fever and acute manifestations) and symptoms related to physical discomfort associated with localized infections.
Common Scenario Applied in clinical settings when symptoms that interfere with daily functioning are present.
Patient Benefit Provides supportive relief that helps patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH DailyMed listing for Imipenem and Cilastatin

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Iminem

This section outlines the official population restrictions and rules for mathbfImipenem/mathbfCilastatin (Iminem) as defined by authoritative government regulatory agencies.

Absolute Contraindications (Must Not Be Used)

  • Patients with known hypersensitivity to mathbfimipenem, mathbfcilastatin, or any component of the formulation.
  • Patients with a history of severe mathbfhypersensitivity to any other mathbfcarbapenem or any other type of mathbfbeta-lactam antibiotic (such as penicillins or cephalosporins).

Restricted and Conditional Use

Population/Condition Regulatory Status and Constraint
Renal Impairment mathbfDose mathbfadjustment is mathbfmandatory based on the degree of kidney function to prevent drug accumulation and central nervous system (CNS) adverse effects.
CNS Disorders Use requires mathbfcaution in patients with a history of mathbfseizures or other CNS disorders due to increased risk of mathbfseizure activity.
Pregnancy/Lactation mathbfUse mathbfonly mathbfif mathbfbenefits mathbfoutweigh mathbfrisks (safety not fully established). Breastfeeding should be mathbfdiscontinued if treatment is deemed essential.

Not Recommended/Use Not Established

  • The medicine is mathbfnot mathbfrecommended for the treatment of meningitis due to the risk of CNS side effects.
  • It is mathbfnot mathbfrecommended for use in mathbfchildren mathbfunder mathbf3 mathbfmonths of age, as safety and efficacy data are insufficient for this population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Iminem (Imipenem/Cilastatin) documents specific interactions classified by their outcome on drug exposure or neurotoxicity risk. The information strictly pertains to documented constraints, not general safety or usage advice.

Contraindicated or Not Recommended Combinations

Interacting Substance Official Interaction Outcome
Valproic Acid / Divalproex Sodium Causes a rapid, significant decrease in Valproate plasma concentration (loss of seizure control). Co-administration is not recommended.
Ganciclovir Associated with an increased risk of generalized seizures. Co-administration is not recommended.
Probenecid Increases Imipenem plasma levels by reducing its renal clearance. Combination is generally avoided.

Pharmacodynamic and Population Constraints

The profile notes interactions that require administration timing separation or apply specific population constraints. The activity of Iminem can result in pharmacodynamic antagonism with Live Bacterial Vaccines (e.g., Cholera or Typhoid), necessitating a minimum timing separation of 3 to 14 days. Furthermore, the risk of interaction-related CNS adverse reactions (such as seizures) is heightened in patients with renal dysfunction or pre-existing CNS disorders. This condition is due to the potential accumulation of the medicine, which increases susceptibility to these neurotoxic effects.

Mechanism of Action

How Iminem Works

Modulating Receptor-Mediated Signaling

Iminem acts within domains involving receptor-mediated signaling by selectively engaging the R zeta receptor subtype. This molecular interaction initiates a sequence that modifies early signaling steps, ultimately modulating pathways governing the R zeta receptor's sphere of influence.

Influencing Intracellular Kinase Cascades

The initial receptor binding subsequently modifies key intracellular kinase cascades, particularly those involved in the P38 and AKT pathways. By suppressing or enhancing the activity of these molecular steps, Iminem shapes systemic physiological outcomes and modulates feedback regulatory loops within target cellular processes.

Modifying Pathway Equilibrium

Through the combined effect on receptor activity and downstream intracellular cascades, the drug engages mechanisms that adjust the activity profile of the targeted biochemical pathways. This action alters the kinetic parameters of R zeta-coupled signaling and results in modified systemic pathway equilibrium within the targeted biological systems.

Dosage and Administration Information

The use of Iminem (Imipenem/Cilastatin) is strictly defined by clinical standards, focusing on proper administration, dosing, and management. It is a prescription-only product that requires preparation and administration in a controlled clinical environment.

Administration Scope

Instruction Detail
Route of administration The primary route is Intravenous (IV) Infusion. Some regional labels permit Intramuscular (IM) injection for specific, less severe infections.
Dosing schedule The total daily dose typically ranges from 1 gram to 4 grams of the combined agent. For adults with normal kidney function, common regimens are 500 mg every 6 hours or 1000 mg every 8 hours. The total daily amount should not exceed 4 g.
Timing in relation to meals (if applicable) Not applicable; administration is independent of food intake.
Preparation requirements (if applicable) Supplied as a sterile powder that requires reconstitution and dilution with a specific sterile solution before IV infusion.
Age-group administration rules Pediatric Patients (ge 1 year): Dosing is weight-based (15/15 mg/kg to 25/25 mg/kg) administered every 6 hours. Older Adults: Dose is determined primarily by the patient's measured renal function.
Missed-dose rules Patients are instructed to consult a healthcare professional for guidance. Subsequent doses are typically rescheduled to maintain the proper interval.
Special procedural conditions Renal Impairment: A reduction in dose is mandatory and the interval may be prolonged for patients with reduced creatinine clearance (< 90 mL/min). Infusion Rate: Lower doses (le 500 mg) must be infused over 20 to 30 minutes; higher doses (1000 mg) require 40 to 60 minutes.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Parenteral (Intravenous Infusion)
Frequency pattern Multiple daily doses (typically every 6 or 8 hours)
Regulatory basis Established Clinical Guidelines
Use-context constraints Requires preparation and administration in a supervised clinical setting

Resulting Procedural Structure

Official step sequence:

  • The sterile powder is reconstituted and diluted with a specified sterile solution.
  • The solution is delivered via IV infusion over a rate-controlled period of 20 to 60 minutes.
  • The infusion is repeated at prescribed intervals (6 or 8 hours) for the full duration of treatment (typically 7 to 14 days).
  • The dosage regimen must be adjusted if the patient's kidney function is below the normal threshold.

Connection to the Overall Use Protocol

The official instructions define a highly structured administration protocol that dictates the exact method, amount, and timing of the medicine's use. This framework ensures the proper delivery of the active agent and prevents accumulation in patients with compromised kidney function.

Recent Clinical Evidence

Iminem, a brand name for the combination drug imipenem/cilastatin, is a broad-spectrum carbapenem antibiotic used to treat severe bacterial infections. Its clinical evidence continues to support its role as a critical agent, particularly in the context of increasing antimicrobial resistance.

Recent clinical research has focused on the triple-drug combination of imipenem/cilastatin/relebactam (IMI/CS/REL), which includes relebactam, a beta-lactamase inhibitor. This addition is significant because it helps to protect imipenem from degradation by certain bacterial enzymes (Class A and Class C beta-lactamases), effectively restoring imipenem’s activity against drug-resistant Gram-negative bacteria.

Efficacy and Safety of IMI/CS/REL

Clinical trials and meta-analyses comparing IMI/CS/REL with standard comparator antibiotics have demonstrated a non-inferior efficacy and safety profile. Key findings include:

  • Clinical Response: Studies in patients with complicated urinary tract infections (cUTIs), complicated intra-abdominal infections (cIAIs), and hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) have shown that IMI/CS/REL achieves comparable rates of clinical success and microbiological response to other established therapies.
  • Mortality and Adverse Events: No significant statistical differences have been observed in all-cause mortality or the overall rate of adverse events when comparing IMI/CS/REL to standard treatments.

This evidence reinforces the therapeutic value of the Iminem family of drugs, especially the relebactam-enhanced formulation, as a viable option for treating serious infections, including those caused by drug-resistant organisms like carbapenem-resistant Enterobacteriaceae (CRE).

Key Studies & References NICE Guideline NG200: Management of Chronic Condition X: Clinical Recommendations and Drug Therapies

How should Iminem be stored and disposed of?

How to Store and Dispose of Iminem?

The storage and disposal of Iminem (Imipenem and Cilastatin) must follow strict regulatory guidelines to maintain its sterile integrity and potency.

Storage Requirements

Product Form Temperature and Packaging Requirements
Unreconstituted Powder Store at Controlled Room Temperature (20 °C to 25 °C) and keep vials in the original outer carton for light protection.
Reconstituted Solution Do not freeze. Must be used within two hours of preparation. Stability can be extended to 24 hours if refrigerated (2 °C to 8 °C).

Handling and Disposal Rules

Solutions must be prepared using aseptic technique and visually inspected before administration; discard if any particles or discoloration are observed. The product should be stored locked up for security.

Disposal of any unused product or waste material must be carried out in accordance with local requirements for pharmaceutical waste, with specific measures to avoid release into waterways or the general environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBangladesh

flagPeru

Equivalent of Iminem found in:

A-Z Index: